SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

iShares Trust - iShares Russell 2000 Index Fund

iShares Russell 2000 ETF

The iShares Russell 2000 ETF (IWM) is seeing intense community debate as traders weigh its persistent structural lag behind tech-heavy indices against technical signals of potential consolidation and bearish sentiment from asset managers. Investors are actively discussing the decoupling of small caps in calm markets versus their high-beta convergence during macro volatility, while monitoring key technical levels amidst broader concerns about market valuation and interest rate trends.

Strategy, Inc. engages in the development of fixed-income instruments that provide investors varying degrees of economic exposure to bitcoin. It executes bitcoin acquisition, capital management, and capital markets strategies. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Tysons Corner, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

MSTR is trending as investors debate the sustainability of its leverage-heavy strategy and the recent price decline of its associated preferred stock, STRC. The community is heavily divided, with critics labeling the stock a ponzi scheme while vocal bulls continue to advocate for buying the dip.

Transocean Ltd. engages in the provision of offshore contract drilling services for oil and gas wells. It also owns and operates offshore drilling fleets such as ultra-deepwater, harsh environment, deepwater, and midwater rigs. The company was founded in 1953 and is headquartered in Steinhausen, Switzerland.

Transocean Ltd

Transocean (RIG) is experiencing significant market attention as it approaches its upcoming earnings report, driven by a surge in offshore contract backlog and the potential re-rating of its stock through its pending merger with Valaris. Investors are closely monitoring the company's progress in deleveraging its balance sheet and securing higher day rates, while community discussions remain heavily focused on geopolitical risks in the Strait of Hormuz and their potential to catalyze long-term structural demand for offshore energy exploration.

Caterpillar, Inc. engages in the business of manufacturing construction and mining equipment, off-highway diesel and natural gas engines, industrial gas turbines, and diesel-electric locomotives. It operates through the following segments: Construction Industries, Resource Industries, Power and Energy, and All Other. The Construction Industries segment is involved in supporting customers using machinery in infrastructure and building construction applications. The Resource Industries segment offers machinery in mining, heavy construction, quarry, and aggregates. The Power and Energy segment focuses on reciprocating engines, turbines, diesel-electric locomotives, and related services across industries serving oil and gas, power generation, industrial, and transportation applications including marine- and rail-related businesses. The All Other segment includes activities such as the business strategy, product management and development, manufacturing, and sourcing of wear and maintenance components products, parts distribution, integrated logistics solutions, distribution services responsible for dealer development, and administration. The company was founded on April 15, 1925, and is headquartered in Irving, TX.

Caterpillar Inc.

Caterpillar is hitting record highs, driven by strong industrial demand for infrastructure and data center construction, leading to multiple analyst price target upgrades and a dividend increase. While some investors worry about overvaluation and historical cyclicality, the broader community remains focused on the company's resilient cash flow and its role as a key beneficiary of global industrial capex.

Harrow, Inc. engages in the development, production, and sale of innovative medications. It operates through the following segments: Pharmaceutical Compounding and Pharmaceutical Drug Development. The Pharmaceutical Compounding segment focuses on the operations of the ImprimisRx business. The company was founded by Mark L. Baum and Robert J. Kammer on January 11, 2006 and is headquartered in Nashville, TN.

Harrow Inc

Harrow Health Inc

Harrow Health is trending as the community anticipates accelerated revenue growth driven by the expansion of its sales force and multiple upcoming product launches. Investors are focused on the long-term potential of the firm's retina portfolio and strong prescription data, fueling speculation that the stock is poised for significant upside as it scales into a larger commercial platform.

Hedera is a decentralized public network where developers can build secure, fair applications with near real-time consensus. The platform is owned and governed by a council of global innovators including Avery Dennison, Boeing, Deutsche Telekom, DLA Piper, FIS (WorldPay), Google, IBM, LG Electronics, Magalu, Nomura, Swirlds, Tata Communications, University College London (UCL), Wipro, and Zain Group.   The Hedera Consensus Service (HCS) acts as a trust layer for any application or permissioned network and allows for the creation of an immutable and verifiable log of messages. Application messages are submitted to the Hedera network for consensus, given a trusted timestamp, and fairly ordered. Use HCS to track assets across a supply chain, create auditable logs of events in an advertising platform, or even use it as a decentralized ordering service.

Hedera Hashgraph

Hedera Hashgraph is currently a focal point for community debate, with investors divided between those accumulating through market volatility and those frustrated by long-term price suppression and token dilution. While the community highlights its institutional partnerships and enterprise-grade infrastructure as primary catalysts for potential future utility, many participants are expressing skepticism and impatience regarding the asset's stagnant performance.

TOSHI

Toshi is gaining community attention as investors speculate on potential AI-driven utility and upcoming ecosystem developments within the Base network. Participants are actively discussing accumulation strategies and waiting for increased volume to trigger a move from consolidation back toward previous highs.

Algorand is a scalable, secure, and decentralized digital currency and smart contract platform. Its protocol uses a variation of Proof-of-Stake (PoS) called Pure PoS (PPoS) to secure the network and reach consensus on block production. Developers can build decentralized applications (dApps) using familiar programming languages, including Python, which Algorand supports natively. Its infrastructure enables various use cases, including payment systems, digital identity solutions, supply-chain tracking, and financial services. The protocol's architecture allows for tokenization of assets and the development of smart contracts, while its technical specifications support both retail users seeking basic transaction capabilities and enterprises requiring more, complex, blockchain solutions.

Algorand

Algorand is currently trending due to a significant surge in interest fueled by recent reports that Google cited the protocol multiple times in a major paper regarding post-quantum cryptography. Investors are actively discussing this validation of its technical infrastructure, alongside community speculation about potential institutional adoption and the potential for a broader recovery in altcoin sentiment.

Celestica, Inc. engages in the provision of supply chain solutions globally to equipment manufacturers and service providers. It operates through the Advanced Technology Solutions (ATS) and Connectivity and Cloud Solutions (CCS) segments. The ATS segment includes aerospace and defense, industrial, smart energy, health tech, and capital equipment businesses. The CCS segment consists of enterprise communications, telecommunications, servers, and storage businesses. The company was founded in 1994 and is headquartered in Toronto, Canada.

Celestica, Inc. - Ordinary Shares (Subordinate Voting)

Celestica, Inc.

Celestica is currently trending as investors look ahead to earnings, with heavy community debate centering on whether the stock will repeat its historical pattern of volatile post-earnings sell-offs or continue its aggressive momentum driven by hyperscaler AI infrastructure demand. Market participants are intensely focused on the company's ability to maintain high-growth guidance while navigating supply chain constraints, making it a focal point for institutional capital rotation into critical hardware and connectivity providers.

Bittensor is an open-source protocol that powers a decentralized, blockchain-based machine learning network. Machine learning models train collaboratively and are rewarded in TAO according to the informational value they offer the collective. TAO also grants external access, allowing users to extract information from the network while tuning its activities to their needs.  Ultimately, BitTensors vision is to create a pure market for artificial intelligence, an incentivized arena in which consumers and producers of this valuable commodity can interact in a trustless, open and transparent context.  Bittensor enables:  -A novel, optimized strategy for the development and distribution of artificial intelligence technology by leveraging the possibilities of a distributed ledger. Specifically, its facilitation of open access/ownership, decentralized governance, and the ability to harness globally-distributed resources of computing power and innovation within an incentivized framework.  -An open-source repository of machine intelligence, accessible to anyone, anywhere, thus creating the conditions for open and permission-less innovation on a global internet scale.  -Distribution of rewards and network ownership to users in direct proportion to the value they have added.

Bittensor

Bittensor (TAO) is trending as investors weigh its potential as decentralized AI infrastructure against concerns about project governance and centralization following the recent departure of a major subnet operator. The community remains divided between long-term bulls accumulating on dips to capitalize on the project's vision and skeptical traders voicing caution over market volatility and project leadership.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Corcept Resubmits NDA for Relacorilant in Cushing's Syndrome

CORT resubmits relacorilant NDA for Cushing's syndrome, with updated analyses and data from multiple clinical studies supporting the filing.

Corcept Resubmits New Drug Application for Relacorilant as a Treatment for Patients with Cushings Syndrome

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced it has resubmitted...

CORT Stock Rises 42% in a Month: Here's What You Should Know

Corcept shares surge 42% in a month as relacorilant advances in Cushing's syndrome and Lifyorli approval to expand the company's revenue base.

Corcept Presents New Data at ADA: Improved Outcomes in Patients Receiving a GLP-1 with Difficult-to-Control Type 2 Diabetes and Hypercortisolism Treated with Korlym

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced the presentation of...

Why Is United Therapeutics (UTHR) Down 3.8% Since Last Earnings Report?

United Therapeutics (UTHR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Corcept Presents New Data at ASCO 2026: Lifyorli Overall Survival Across All Subgroups of Patients with Platinum-Resistant Ovarian Cancer, Including Those with Recent Taxane Exposure

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today presented new overall survival...

CORT to Resubmit NDA for Relacorilant in Cushing's Syndrome, Stock Up

Corcept stock jumps after the company announces plans to resubmit relacorilant's NDA for treating Cushing's syndrome.

CORT Stock Hits Highest Levels In 2026 – Cushing’s Syndrome Drug NDA Resubmission Extends 5-Session Rally

Equity

 Corcept said it will resubmit the new drug application in the coming weeks after positive talks with the U.S. Food and Drug Administration.

Corcept to Resubmit its New Drug Application for Relacorilant as a Treatment for Patients with Cushings Syndrome

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced it will resubmit its...

Wall Street Analysts Believe Corcept (CORT) Could Rally 43.32%: Here's is How to Trade

The consensus price target hints at a 43.3% upside potential for Corcept (CORT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Corcept Therapeutics, Inc. engages in the business of discovering and developing pharmaceutical products and medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders by modulating the effects of the hormone cortisol. The company was founded by David B. Singer and Joseph K. Belanoff on May 13, 1998 and is headquartered in Redwood City, CA.

Corcept Therapeutics Inc

Bearish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$79.91
Prev Close	$81.75
Open	$82.82
Dividend Yield	0.00%
50-Day Moving Average	$58.94
Beta	1.37
Avg. Volume	1.3M
PE Ratio	228.31

52-Week High	$91.00
52-Week Low	$28.66
Market Capitalization	$8.58B
EPS (Annual)	$0.8182
Price to Book	13.44
Revenue Per Employee	$1.04M

CORTCorcept Therapeutics Inc

Fundamentals

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest CORT News